To date, 2023 is shaping up to be a relatively brisk year for M&A deals. A recent case in point is Regeneron’s acquisition of Decibel Therapeutics. The centerpiece of the deal is DB-OTO, a gene therapy intended for patients with otoferlin-related hearing loss. The drug is in its first clinical trial. Regeneron agreed to pay…

The pharmaceutical and biotech industries have experienced a surge of high-profile acquisitions and mergers in the first few months of the year, marking a notable trend in pharma M&A 2023. From Merck’s $11 billion acquisition of Prometheus Biosciences to Pfizer’s $43 billion purchase of Seagen, these deals highlight a focus on strengthening core assets and…

As the threat of a global recession looms in 2023, the pharmaceutical industry is beginning to feel the pressure, with several pharma and biotech companies conducting layoffs and reducing their workforces. Among them is the Ferring Research Institute in San Diego, which has announced plans to lay off all 89 of its employees in May.…

The Freeze-Lock cryo label from Schreiner MediPharm (Oberschleissheim, Germany) is suited for mRNA-based vaccines. The labels also support many cell and gene therapy medications and clinical trials, given their ability to withstand subzero storage and transport temperatures required by pharmaceutical and biopharmaceutical manufacturers and clinical researchers. Schreiner MediPharm notes that conventional labels fail to offer…

San Sebastián, Spain–headquartered Viralgen, has opened a new factory in Basque Country in northern Spain. The company focuses on manufacturing adeno-associated virus (AAV) vectors, which are used in gene therapy and some vaccines. Since 2018, Viralgen has offered AAV manufacturing for customers working in preclinical through Phase 2 development programs. The company has licensed its…